High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study)

K Fritsch; B Kasenda; E Schorb; P Hau; J Bloehdorn; R Möhle; S Löw; M Binder; J Atta; U Keller; H-H Wolf; S W Krause; G Heß; R Naumann; S Sasse; C Hirt; M Lamprecht; U Martens; A Morgner; J Panse; N Frickhofen; A Röth; C Hader; M Deckert; H Fricker; G Ihorst; J Finke; G Illerhaus

doi:10.1038/leu.2016.334

High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study)

Standard

High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study). / Fritsch, K; Kasenda, B; Schorb, E; Hau, P; Bloehdorn, J; Möhle, R; Löw, S; Binder, M; Atta, J; Keller, U; Wolf, H-H; Krause, S W; Heß, G; Naumann, R; Sasse, S; Hirt, C; Lamprecht, M; Martens, U; Morgner, A; Panse, J; Frickhofen, N; Röth, A; Hader, C; Deckert, M; Fricker, H; Ihorst, G; Finke, J; Illerhaus, G.

in: LEUKEMIA, Jahrgang 31, Nr. 4, 04.2017, S. 846-852.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Fritsch, K, Kasenda, B, Schorb, E, Hau, P, Bloehdorn, J, Möhle, R, Löw, S, Binder, M, Atta, J, Keller, U, Wolf, H-H, Krause, SW, Heß, G, Naumann, R, Sasse, S, Hirt, C, Lamprecht, M, Martens, U, Morgner, A, Panse, J, Frickhofen, N, Röth, A, Hader, C, Deckert, M, Fricker, H, Ihorst, G, Finke, J & Illerhaus, G 2017, 'High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study)', LEUKEMIA, Jg. 31, Nr. 4, S. 846-852. https://doi.org/10.1038/leu.2016.334

APA

Fritsch, K., Kasenda, B., Schorb, E., Hau, P., Bloehdorn, J., Möhle, R., Löw, S., Binder, M., Atta, J., Keller, U., Wolf, H-H., Krause, S. W., Heß, G., Naumann, R., Sasse, S., Hirt, C., Lamprecht, M., Martens, U., Morgner, A., ... Illerhaus, G. (2017). High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study). LEUKEMIA, 31(4), 846-852. https://doi.org/10.1038/leu.2016.334

Vancouver

Fritsch K, Kasenda B, Schorb E, Hau P, Bloehdorn J, Möhle R et al. High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study). LEUKEMIA. 2017 Apr;31(4):846-852. https://doi.org/10.1038/leu.2016.334

Bibtex

@article{fb052514333f48e2bb0b16afcf5be609,

title = "High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study)",

abstract = "To investigate immuno-chemotherapy for elderly immuno-competent patients (⩾65 years) with newly diagnosed primary central nervous system lymphoma, we conducted a multicentre single-arm trial. One cycle consisted of rituximab (375 mg/m2, days 1, 15, 29), high-dose methotrexate (3 g/m2days 2, 16, 30), procarbazine (60 mg/m2days 2-11) and lomustine (110 mg/m2, day 2)-R-MPL protocol. Owing to infectious complications, we omitted lomustine during the study and consecutive patients were treated with the R-MP protocol. Three cycles were scheduled and repeated on day 43. Subsequently, patients commenced 4 weekly maintenance treatment with procarbazine (100 mg for 5 days). Primary end point was complete remission (CR) after 3 cycles. We included 107 patients (69 treated with R-MPL and 38 with R-MP). In all, 38/107 patients achieved CR (35.5%) and 15 (14.0%) achieved partial remission. R-MP was associated with a lower CR rate (31.6%) compared with R-MPL (37.7%), but respective 2-year progression-free survival (All 37.3%; R-MP 34.9%; R-MPL 38.8%) and overall survival (All 47.0%; R-MP 47.7%; R-MPL 46.0%) rates were similar. R-MP was associated with less ⩾grade 3 toxicities compared with R-MPL (71.1% vs 87.0%). R-MP is more feasible while still associated with similar efficacy compared with R-MPL and warrants further improvement in future studies.",

keywords = "Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Central Nervous System Neoplasms, Female, Humans, Immunologic Factors, Lymphoma, Male, Methotrexate, Neoplasm Staging, Proportional Hazards Models, Quality of Life, Remission Induction, Treatment Outcome, Tumor Burden, Clinical Trial, Phase II, Journal Article, Multicenter Study",

author = "K Fritsch and B Kasenda and E Schorb and P Hau and J Bloehdorn and R M{\"o}hle and S L{\"o}w and M Binder and J Atta and U Keller and H-H Wolf and Krause, {S W} and G He{\ss} and R Naumann and S Sasse and C Hirt and M Lamprecht and U Martens and A Morgner and J Panse and N Frickhofen and A R{\"o}th and C Hader and M Deckert and H Fricker and G Ihorst and J Finke and G Illerhaus",

year = "2017",

month = apr,

doi = "10.1038/leu.2016.334",

language = "English",

volume = "31",

pages = "846--852",

journal = "LEUKEMIA",

issn = "0887-6924",

publisher = "NATURE PUBLISHING GROUP",

number = "4",

}

RIS

TY - JOUR

T1 - High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study)

AU - Fritsch, K

AU - Kasenda, B

AU - Schorb, E

AU - Hau, P

AU - Bloehdorn, J

AU - Möhle, R

AU - Löw, S

AU - Binder, M

AU - Atta, J

AU - Keller, U

AU - Wolf, H-H

AU - Krause, S W

AU - Heß, G

AU - Naumann, R

AU - Sasse, S

AU - Hirt, C

AU - Lamprecht, M

AU - Martens, U

AU - Morgner, A

AU - Panse, J

AU - Frickhofen, N

AU - Röth, A

AU - Hader, C

AU - Deckert, M

AU - Fricker, H

AU - Ihorst, G

AU - Finke, J

AU - Illerhaus, G

PY - 2017/4

Y1 - 2017/4

N2 - To investigate immuno-chemotherapy for elderly immuno-competent patients (⩾65 years) with newly diagnosed primary central nervous system lymphoma, we conducted a multicentre single-arm trial. One cycle consisted of rituximab (375 mg/m2, days 1, 15, 29), high-dose methotrexate (3 g/m2days 2, 16, 30), procarbazine (60 mg/m2days 2-11) and lomustine (110 mg/m2, day 2)-R-MPL protocol. Owing to infectious complications, we omitted lomustine during the study and consecutive patients were treated with the R-MP protocol. Three cycles were scheduled and repeated on day 43. Subsequently, patients commenced 4 weekly maintenance treatment with procarbazine (100 mg for 5 days). Primary end point was complete remission (CR) after 3 cycles. We included 107 patients (69 treated with R-MPL and 38 with R-MP). In all, 38/107 patients achieved CR (35.5%) and 15 (14.0%) achieved partial remission. R-MP was associated with a lower CR rate (31.6%) compared with R-MPL (37.7%), but respective 2-year progression-free survival (All 37.3%; R-MP 34.9%; R-MPL 38.8%) and overall survival (All 47.0%; R-MP 47.7%; R-MPL 46.0%) rates were similar. R-MP was associated with less ⩾grade 3 toxicities compared with R-MPL (71.1% vs 87.0%). R-MP is more feasible while still associated with similar efficacy compared with R-MPL and warrants further improvement in future studies.

AB - To investigate immuno-chemotherapy for elderly immuno-competent patients (⩾65 years) with newly diagnosed primary central nervous system lymphoma, we conducted a multicentre single-arm trial. One cycle consisted of rituximab (375 mg/m2, days 1, 15, 29), high-dose methotrexate (3 g/m2days 2, 16, 30), procarbazine (60 mg/m2days 2-11) and lomustine (110 mg/m2, day 2)-R-MPL protocol. Owing to infectious complications, we omitted lomustine during the study and consecutive patients were treated with the R-MP protocol. Three cycles were scheduled and repeated on day 43. Subsequently, patients commenced 4 weekly maintenance treatment with procarbazine (100 mg for 5 days). Primary end point was complete remission (CR) after 3 cycles. We included 107 patients (69 treated with R-MPL and 38 with R-MP). In all, 38/107 patients achieved CR (35.5%) and 15 (14.0%) achieved partial remission. R-MP was associated with a lower CR rate (31.6%) compared with R-MPL (37.7%), but respective 2-year progression-free survival (All 37.3%; R-MP 34.9%; R-MPL 38.8%) and overall survival (All 47.0%; R-MP 47.7%; R-MPL 46.0%) rates were similar. R-MP was associated with less ⩾grade 3 toxicities compared with R-MPL (71.1% vs 87.0%). R-MP is more feasible while still associated with similar efficacy compared with R-MPL and warrants further improvement in future studies.

KW - Aged

KW - Aged, 80 and over

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Central Nervous System Neoplasms

KW - Female

KW - Humans

KW - Immunologic Factors

KW - Lymphoma

KW - Male

KW - Methotrexate

KW - Neoplasm Staging

KW - Proportional Hazards Models

KW - Quality of Life

KW - Remission Induction

KW - Treatment Outcome

KW - Tumor Burden

KW - Clinical Trial, Phase II

KW - Journal Article

KW - Multicenter Study

U2 - 10.1038/leu.2016.334

DO - 10.1038/leu.2016.334

M3 - SCORING: Journal article

C2 - 27843136

VL - 31

SP - 846

EP - 852

JO - LEUKEMIA

JF - LEUKEMIA

SN - 0887-6924

IS - 4

ER -